Call to action: Explore GLP-1 Drug Therapy Monitoring options from Ulta Lab Tests and choose testing that fits your health history, symptoms, and provider-guided monitoring plan
DOI: Published online: July 1, 2025 Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea Corresponding author: Hye Jin Yoo Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul 08308, Korea E-mail: [email protected] Copyright 2025 Korean Diabetes Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
When p 0.05, we used one-way ANOVA to compare differences between groups
The more hormones targeted, the greater the metabolic impact
The strongest data we have come from standard dosing : In STEP 1, once-weekly semaglutide 2.4 mg plus lifestyle support produced clinically meaningful average weight loss and improvements in cardiometabolic risk factors